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Comparison of weight loss induced by recombinant tumour necrosis
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Summary A comparison has been made of the cachectic effects produced by the transplantable murine
adenocarcinoma of the mouse colon (MAC16) with tumour necrosis factor-a (cachectin). Tumour necrosis
factor-a (TNF-a) produced a dose-related weight reduction that was accompanied by a decrease in both food
and water intake. The degree of weight loss was directly proportional to the decreased food and water intake.
In contrast weight loss produced by the MAC16 tumour occurred without a reduction in fluid or nutrient
intake. Both the MAC16 tumour and TNF-a produced hypoglycaemia and a reduction in the circulatory level
of free fatty acids (FFA), but had opposite effects on the level of plasma triglycerides with the MAC16
tumour-induced cachexia causing a decrease and TNF-a producing an increase. The MAC16 tumour
elaborated a lipolytic factor which caused an immediate release of FFA from adipose tissue. In contrast TNF-a
had no effect on mobilization of adipose triglycerides over a short time period. Both TNF-a and extracts
from the MAC16 tumour caused an enhanced release of amino acids from mouse diaphragm, which was
suppressible with indomethacin and heat labile. No TNF was detected in the MAC16 tumour or in the serum
of tumour-bearing animals. Both tumour and non-tumour-bearing animals responded with a similar elevation
of their serum TNF levels 90min after a single injection of endotoxin. It is concluded that weight loss
produced by TNF-a arises from an anorexic effect and that this differs from the complex metabolic changes
associated with cancer cachexia.
We have been investigating a chemically induced,
transplantable adenocarcinoma of the colon (MAC16),
passaged in inbred NMRI mice as an experimental model of
cachexia (Bibby et al., 1987). This tumour produces weight
loss at small tumour burdens (<1% of the host wcight) and
without a reduction in the intake of either food or water.
The weight loss, which is directly proportional to the tumour
weight, is associated with a decrease in both carcass fat and
muscle dry weight (Beck & Tisdale, 1987). The cachectic
effect of the tumour has been attributed to the production of
both lipolytic and proteolytic factors, which are present in
the circulation of tumour-bearing animals.
Endotoxin-induced cells of the reticuloendothelial system
have been shown to elaborate a mediator called cachectin
(tumour necrosis factor, TNF), which induces a state of
cachexia in recipient animals (Cerami et al., 1985). When
chronically secreted by host macrophages cachectin has been
suggested to contribute to a catabolic state, which ultimately
leads to cachexia (Beutler & Cerami, 1986). Torti et al.
(1985) have shown that cachectin acts to suppress the
biosynthesis of several adipocyte-specific mRNA molecules
and prevents morphological differentiation of pre-adipocytes.
Lipoprotein lipase is one of the many enzymes whose
transcription is suppressed by the action of this hormone
(Price et al., 1986b). Inhibition of lipoprotein lipase would
prevent adipocytes from extracting fatty acids from plasma
lipoproteins for storage. This would result in a net flux of
lipid into the circulation, where the host defence could use it
as an energy source. With chronic infectious challenge,
however, wasting could persist and death would ensue
(Beutler & Cerami, 1986).
In order to evaluate the role of TNF in cachexia we have
compared the parameters contributing to weight loss in
animals bearing the MAC16 tumour with that produced by
human recombinant TNF-ax, and sought to determine the
presence of TNF either in tumour extracts or in the serum of
tumour-bearing mice.
Materials and methods
Animals
Pure strain NMRI mice (age 6-8 weeks) were purchased
from Banting and Kingman, Hull and fed ad libitum a rat
and mouse breeding diet (Pilsbury's, Birmingham, UK). All
animals were given free access to water and both food and
water intake were monitored daily. Fragments of the
MAC16 or MAC13 tumours (1 x2mm in size) were
implanted into the flank by means of a trocar as described
(Bibby et al., 1987). Positive takes can only be identified 14
days after transplantation.
TNF
Human recombinant TNF-a (6x l07Umg-i) was kindly
donated by Boehringer IngelheimLtd., Bracknell, Berks, and
was stored at 4°C. The endotoxin content was
<0.125 EUml- I and there was no proteolytic
contamination. Fresh solutions of TNF-a were made up
daily in 0.9% NaCl and 200,ul of the appropriate con-
centration of TNF-a was injected into the tail veins of
female NMRI mice. Controls were injected with 200u10.9%
NaCI. Body weights and food and water intake were
monitored daily. A second injection of TNF-oa was given 24h
after the first injection. Blood was removed by cardiac
punture from animals under anaesthesia 1 h after the final
injection of TNF-ax.
Metabolite determinations
-Blood glucose was determined on whole blood with the use
of the o-toluidine reagent kit (Sigma Chemical Co., Dorset,
UK). Free fatty acid (FFA) levels were measured in plasma
with a Wako NEFA C kit (Alpha laboratories). Plasma
triglycerides were determined with a triglyceride diagnostic
kit (Sigma Diagnostic, Dorset, UK).
Primed TNF production
Non-tumour-bearing and MAC16 and MAC13 tumour-
bearing male NMRI mice were administered 1.25mgkg-1 E.
coli lipopolysaccharide (Sigma Chemical Co., Dorset, UK) into the tail veins and blood was removed 1.5h later by
cardiac punture from animals under anaesthesia. Blood was
allowed to clot, centrifuged and the resulting serum was used
for TNF determinations.
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TNF assay
TNF was determined by an in vitro method similar to that
previously described by Ruff and Gifford (1981). L929 cells
were seeded at a concentration of 3 x 104 per well into 96-
well flat-bottom microtitre trays (Nunc., Denmark) in 100,]l
RPMI 1640 medium (Gibco Europe, Paisley, Scotland)
containing 10% foetal calf serum, and incubated at 37 C
overnight under an atmosphere of 5% CO2 in air. The
medium was then removed and was replaced with varying
dilutions of TNF-containing medium and actinomycin D
(1 yigml-1) to a final volume of 100jil. Controls contained
only medium and actinomycin D. Internal standards
contained medium with 1 unit of recombinant human TNF
and actinomycin D. The plates were re-incubated for 16 to
18 h and the cells were stained with crystal violet. Rinsed and
dried plates were enumerated spectrophotometrically at
570 nm on a Titerteck Multiscanner (Flow Laboratories) and
the percentage of cell cytotoxicity was calculated as described
by Flick and Gifford (1984, 1986).
Determination of lipolytic activity
The epididymal adipose tissue was removed from male
BALB/c mice and minced in Krebs-Ringer bicarbonate
buffer, pH 7.6. Approximately 50-100mg of the adipose
tissue was incubated with either the MAC16 tumour
supernatant or TNF in a total volume of 0.25 ml of the
Krebs-Ringer buffer. Controls containing adipose tissue and
buffer alone were included in each experiment and the
spontaneous release of free fatty acids (FFA) was subtracted
from the values obtained with tumour present. The release of
FFA by MAC16 tumour extracts was linear up to 2h (Beck
& Tisdale, 1987), and incubations were normally conducted
for a 2 h period at 37 C. The concentration of FFA in the
cell-free supernatants was determined immediately using a
Wako NEFA C kit.
Determination of proteolytic activity
Male BALB/c mice were killed by cervical dislocation and
diaphragms were carefully dissected out, blotted, cut in half,
weighed and each half placed in a stoppered vial containing
0.75 ml Krebs-Ringer bicarbonate buffer and gassed for
20 sec with 5% CO2 in air. Preincubations were carried out
for 30min at 37°C, and the diaphragms were then blotted
and transferred to clean vials containing either tumour
extract or TNF and the Krebs-Ringer buffer, in a total
volume of 0.75 ml. The vials were gassed and incubated for a
further 2h at 37°C. Incubations were terminated by mixing
0.5 ml assay mixture with 0.125 ml of cold 50% TCA, mixing
and centrifuging for 10min at 3000rpm. The supernatants
were neutralised with I N NaOH and 0.2ml of the
neutralised sample was mixed with 1 ml of ninhydrin reagent,
held in a boiling water bath for 20min, and after dilution to
5ml with n-propanol:water (1: 1), the concentration of amino
acids was determined spectrophotometrically at 570nm. The
spontaneous release of amino acids from the diaphragms in
the absence of any additions was subtracted from the final
readings.
Results
The characteristics of weight loss produced by the MAC16
adenocarcinoma passaged in NMRI mice has previously
been reported (Bibby et al., 1987, Beck and Tisdale, 1987).
Briefly weight loss starts to occur when the tumour mass
exceeds 0.1 g and reaches 10g in a 30g male mouse when the
tumour mass is 0.7g, representing just 2% of the weight of
the animal. Both muscle and adipose mass decrease in direct
proportion to the weight of the tumour (Beck & Tisdale,
1987). The average food intake in MAC16 tumour-bearing
animals (15.1 +0.6kcalday-1) is not significantly different
from that in non-tumour-bearing animals
(I14.9+0.9 kcal day - 1). Also the water intake in tumour-
bearing animals (4.6+0.27mlday- 1) does not differ from
that of controls (4.8+0.16mlday- 1).
We have used female NMRI mice to study weight loss
induced by TNF-a since they display a less aggressive
behaviour than males, which may result in selective in-
dividuals being deprived food and water. Human recombin-
ant TNF-a administered i.v. causes a dose-related weight loss
after two separate injections over a 24h period (Figure 1),
which is significantly greater than saline injected controls at
all concentrations of TNF-at employed. Qualitatively similar
results were obtained with murine recombinant TNF-cx,
obtained from Dr W. Fiers, Biogent, Belgium (Marmenout
et al., 1985). No mortality was observed with any of the
concentrations of TNF-a. This weight loss differs from that
observed in MAC16 tumour-bearing animals in that it is
associated with a dose-dependent decrease in both food
(Figure 2) and water (Figure 3) consumption. The decrease
in food and water intake is directly proportional to the
decrease in body weight (Figure 4).
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Figure I Effect of acute administration of TNF-a on the weight
of female NMRI mice. Human recombinant TNF-a was
administered i.v. as two separate injections over a 24h period
and the animals were killed 1 h after the last injection. The values
represent the means + s.e.m. for 4 to 11 animals for each
concentration of TNF. *P<0.01, **P<0.001 from control by
Students t test.
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Figure 2 Effect of acute administration of TNF-a on food
consumption of female NMRI mice during a 24h period. The
values represent the means + s.e.m. for 4 to 11 animals for each
concentration of TNF-a. *P<0.0,**P<0.0, ***P<0.005 from
control by Students t test.TUMOUR NECROSIS FACTOR AND CACHEXIA 387
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Figure 3 Effect of acute administration of TNF-a on water
consumption of female NMRI mice during a 24h period. The
values represent the means + se.m.for 4 to 11 animals for each
concentration of TNF-a. *P<0.05, **P<0.01, ***P<0.005 from
control by Students t test.
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Figure 4 Variation of weight loss during a 24h period after
administration of TNF-a with the difference in food
(kcal/mouse) and water (ml) consumption between a saline
infused group and the TNF-a treated groups. The results were
fitted to a linear model by means of a least squares analysis
(r = -0.99).
Animals bearing the MAC16 tumour display a reduced
blood glucose level. TNF-a treated mice also show a highly
significant dose-related hypoglycaemia, which is much more
pronounced than observed in weight-losing tumour-bearing
animals (Table I). Plasma triglyceride levels are also reduced
in tumour-bearing animals, whereas TNF-oa causes an
increase in circulatory triglycerides, presumably due to an
inhibition of adipocyte lipoprotein lipase activity (Table I).
Plasma levels of FFA are reduced after TNF-a adminis-
tration, as might be expected from an inhibition of
lipoprotein lipase and also in tumour-bearing animals,
possibly due to increased tumour utilization.
The loss of body fat in MAC16 tumour-bearing animals
has been correlated with the presence of a lipolytic substance
produced by the tumour (Beck and Tisdale, 1987). This
material is quantitated by the extent of release of FFA from
mouse epididymal adipocytes. The results in Table II show
that while extracts of the MAC16 tumour cause an enhanced
release of FFA, TNF-a has no effect on the release of FFA
under the conditions of the assay up to a concentration of
4 x 105 units ml-'. The MAC16 tumour also has high levels
of proteolytic activity, which may be responsible for the
muscle wasting (Beck & Tisdale, 1987) (Figure 5). Using the
mouse diaphragm as a model of skeletal muscle, TNF-oa at
high concentrations also causes an enhanced release of
amino acids (Figure 5). This effect is not due to con-
tamination by endotoxin, since when the TNF-a is heated to
70°C for 15min, which should destroy the TNF, but does
not affect endotoxin, the proteolytic activity is completely
destroyed. The proteolytic effect of TNF-a is almost com-
pletely suppressed by indomethacin and human a-I anti-
trypsin. The proteolytic activity of the MAC16 tumour
extract is also partially suppressed by indomethacin and
there is a synergistic inhibition by a combination of indo-
methacin and antitrypsin (Figure 5). Proteolysis by trypsin is
also inhibited by indomethacin. An enhanced amino acid
release is also observed when diaphragms are incubated in
the presence of PGE2 or PGEJ, but not in the presence of
PGFia or PGF2,, (Table III).
No TNF was detected either in the MAC16 tumour or in
the serum of tumour-bearing mice using the L929 cyto-
toxicity assay. TNF was detected in the serum of non-
tumour-bearing animals and in the serum of animals bearing
the MAC16 and the non-cachexia inducing colon adeno-
carcinoma, MAC13, 90min after a single i.v. injection of
25jug endotoxin (Figure 6). However, there was no difference
in the extent of response between non-tumour-bearing
animals and animals bearing either type of tumour or in the
levels of TNF in the two tumour types.
Discussion
The MAC16 tumour can be considered as an appropriate
model for human cancer where weight loss occurs due to the
biochemical effect of the tumour in patients with adequate
Table I Effect of recombinant TNF-a and the MAC16 tumour on the plasma level of
glucose, FFA and triglyceridesa
Glucose FFA Triglyceride
Treatment (mg100ml-1) (mg 100ml-) (mM)
Non-tumour-bearing 136+5 29+2 1.15+0.11
Non-tumour-bearing (saline) 124+5 32+5 0.93+0.31
MAC16 tumour-bearing 108 + 1 lb 10+ le 0.50+0.07d
TNF-a 0.25mgkg'- 82+8b 17+2b 2.72+0.15c
TNF-ac 0,5mgkg-1 74+7d 1S+3b 2.52+0.14c
TNF-oa 0.75mgkg'- 59+4d 19++3b 2.24+0.32c
aResults are given as means+s.e.m_ bp<0.05 from non-tumour-bearing animals;
cP<0.01 from non-tumour-bearing saline infused animals; dp<0.001 from non-tumour-
bearing saline infused animals; ep<0.005 from non-tumour-bearing saline infused
animals.
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Table II Effect of recombinant TNF-a and the MAC16 tumour on
the release of FFA from adipocytes
Addition nmol FFA mgprotein 1 h - I +s.e.m.a
MAC16 tumour extract 148.1 +8.3c
4 x 105 units TNF-axb 0
4 x 104 units TNF-acb 0
4 x 103 units TNF-acb 0
aResults are expressed as means+s.e.m.; bTNF-a in units ml-1 of
the assay mixture; 'Mean of 11 determinations.
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Figure 6 Production of TNF by endotoxin in unprimed mice.
The TNF concentration in serum (U) and tumour (E3) was
determined by means of the L929 cytotoxicity assay as described
in Materials and methods.
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Figure 5 Rates of release of amino acids from mouse
diaphragms by MAC16 tumour homogenate and TNF-x. (a)
103U TNF-a per assay. (b) 104U TNF-a per assay. (c) 105U
TNF-cx per assay. (d) 105U TNF-a+ 1.0mM indomethacin. (e)
105U TNF-a+ 1 mgmlrn 1-1 antitrypsin. (f) MAC16 tumour
extract; 2.9mg protein ml-1. (g) MAC16 tumour extract
+ 1.0mM indomethacin. (h) MAC16 tumour extract +1 mgml-1
antitrypsin. (i) MAC16 tumour extract + 1.0mM
indomethacin+1 mg ml 1 antitrypsin. (j) Trypsin; 0.1 mgml -l.
(k) Trypsin 0.1 mgml -1+ 1.0mM indomethacin. (b) and (c)
P<0.05 from Krebs Ringer buffer alone. (d) and (e) P<0.05
from (c). (c) P<0.05 from (f). (h) and (i) P<0.001 from (f), by
Students t test.
Table III Effect of prostaglandins on the release of
amino acids from mouse diaphragm
Concentration nmoles amino acid released
(ugml-1) g.diaphragm- 1 2h- +s.e.m.
PGE1 5 0.028+0.024
10 0.085+0.006a
20 0.234+0.066b
PGE, 5 0.069+0.022b
10 0.242+0.079b
20 0.369+0.036a
PGF1 5 0.000
10 0.000
20 0.040
PGF2 5 0.000
10 0.000
20 0.000
ap <0.005 from spontaneous
spontaneous release.
release; bp <0.05 from
nutrient intake and without intestinal malfunction. In
contrast TNF induces a state of anorexia and the ensuing
weight loss is directly proportional to the decrease in food
and water intake. A similar effect has been observed in mice
injected with dialyzed conditioned medium obtained from
lipopolysaccharide-induced peritoneal macrophages (Cerami
et al., 1985). Although all the experiments have been
performed with human TNF-oa similar results were obtained
with murine TNF-cx. Marmenout et al. (1985) have shown
that in spite of the apparent species specificity of TNF,
human TNF is about 80% homologous to mouse TNF, and
its hydrophilicity plot is also very similar.
The weight loss produced by both TNF-ax and the MAC16
tumour is associated with hypoglycaemia, although TNF
produces a more marked and possibly life-threatening
decline in blood glucose levels. While administration of
lipopolysaccharide has been shown to induce hypoglycaemia,
Satomi et al. (1985) reported no hypoglycaemia in mice
administered highly purified TNF. However, Kettlehut et al.
(1987) have recently demonstrated large biphasic changes in
blood glucose levels after TNF injection, with an initial
hyperglycaemia followed by a sharp decrease in blood
glucose. It has been suggested (Kettlehut et al., 1987) that
TNF may stimulate glucose uptake and oxidation contribut-
ing to the severe hypoglycaemia. In contrast the
hypoglycaemia observed in animals bearing the MAC16
tumour probably arises from an increased consumption of
glucose by the tumour (Tisdale & Brennan, 1986).
The MAC16 tumour and TNF-cx differ as regards their
effect on lipid metabolism in weight-losing animals. Thus,
whereas animals bearing the MAC16 tumour have a reduced
circulatory level of both FFA and triglycerides, TNF-oa
causes an increase in plasma triglyceride levels probably due
to an inhibition of lipoprotein lipase activity. While
lipoprotein lipase activity has been shown to be decreased in
mice with the development of Sarcoma 180 (Masuno &
Okuda, 1986) we have no evidence for an effect on
lipoprotein lipase activity in animals bearing the MAC16
tumour, despite a massive loss of adipose tissue. This
catabolism of adipose tissue has been attributed to the
production by the tumour of a lipolytic factor (Beck &
Tisdale, 1987). However, we have observed no increased
breakdown of stored triglycerides in adipose tissue in the
presence of TNF-ax. While Kawakami et al. (1987) have
reported that TNF-x increased the lipolysis of stored fat in
3T3-L1 adipocytes, even in the presence of 50ngml-1 of
insulin, Price et al. (1986b) have shown that while crude
preparations of TNF were able to suppress the activity of
key lipogenic enzymes and stimulate lipolysis, recombinant
TNF-a had no effect on either the ability of the adipocytes
to synthesize and store or to mobilize triacylglycerols. The
lipolytic activity of stimulated macrophages was attributed to
interleukin 1, which both suppressed lipoprotein lipase
activity and stimulated lipolysis (Price et al., 1986a).
Another possible reason for the absence of lipolysis we
observed with our TNF-oa preparation was the relatively
short incubation time that we employed (2h). Kawakami et
al. (1987) did not observe an increase in glycerol production
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in 3T3-L1 cells until 12h after the addition of TNF-a, after
which there was a linear increase in production up to 24h.
Kettlehut et al. (1987) have shown that the toxic and
metabolic effects of TNF probably arise from an increased
prostaglandin E2 production since the cyclooxygenase
inhibitors indomethacin or ibuprofen administered before
TNF reduced the lethality and changes in blood glucose. We
have shown (Beck & Tisdale, 1988) that the lipolytic
substance elaborated by the MAC16 tumour is not a prosta-
glandin since indomethacin had no effect on FFA release at
concentrations up to 1 mM.
The MAC16 tumour also elaborates a serine-protease
when measured by an accelerate rate of release of amino
acids from mouse diaphragm as a model of skeletal muscle
(Beck & Tisdale, 1987). Using a similar assay we have
detected a proteolytic activity associated with high level of
TNF-ax. This activity was not due to the small amount of
endotoxin contamination since it was destroyed by heating,
and not due to the presence of endogenous proteases in the
TNF-a preparation (Boehringer Ingelheim, pers. comm.).
Proteolysis induced by both TNF-a and the MAC16 tumour
extract is suppressible by indomethacin suggesting the
possibility of a prostaglandin intermediate. We have shown
that prostaglandins of the E series, but not of the F, are also
effective in inducing amino acid release from mouse
diaphgram. PGE2 is believed to be an important stimulus for
the production of intracellular proteases (Rodemann &
Goldberg, 1982). Moreover, TNF-a has been reported to
stimulate collagenase and prostaglandin E2 production by
human synovial cells and dermal fibroblasts (Dayer et al.,
1985). This suggests that the enhanced release of amino acids
from mouse diaphragm in the presence of TNF is due to an
elevation of PGE2 levels.
We have been unable to detect TNF either in the MAC16
tumour, or in the serum of tumour-bearing animals. Animals
bearing either the MAC16 or the non-cachexing-inducing
MAC13 colon adenocarcinomas do not respond to
endotoxin with an increased TNF production compared with
non-tumour bearing controls. This negates against a syner-
gistic influence of the presence of a tumour on TNF
production in response to endotoxin.
The results suggest that TNF has no role in the induction
of cachexia seen in animals bearing the MAC16 tumour.
Although we have compared the chronic secretion of factors
produced by the MAC16 tumour with the acute effects of
TNF we have shown (Mahony and Tisdale, unpublished
results) that chronic exposure to TNF does not differ
appreciably from the acute effects. Furthermore the weight
loss produced by TNF appears to arise from an anorexic
effect of this agent and this differs from the changes
associated with cancer cachexia.
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